EQUITY RESEARCH MEMO

HiArc

Generated 5/9/2026

Executive Summary

Conviction (model self-assessment)65/100

HiArc is a US-based engineering and manufacturing partner for complex diagnostic and life science systems, offering end-to-end services from concept design to compliant manufacturing and post-market support. Founded in 2020 and headquartered in San Francisco, the company specializes in deep collaboration with clients and adherence to high regulatory standards such as ISO 13485. As a private firm with no disclosed funding or stage, HiArc operates in the growing digital health and AI/machine learning sectors, positioning itself as a critical enabler for medical device and diagnostic innovators seeking to bring complex systems to market. Given the increasing demand for outsourced manufacturing expertise in regulated industries, HiArc is well-placed to capture market share, though its lack of public traction and limited profile suggest early-stage risk.

Upcoming Catalysts (preview)

  • Q4 2026Secures ISO 13485:2016 certification or major renewal75% success
  • Q1 2027Announces partnership with a leading diagnostic startup40% success
  • H1 2027Closes Series A funding round to scale operations50% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)